Literature DB >> 1456889

Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.

R Wagner1, S Modrow, T Böltz, H Fliessbach, M Niedrig, A von Brunn, H Wolf.   

Abstract

To reduce the opportunities for human immunodeficiency virus type 1 (HIV-1) to evade vaccine induced immunity, the development of subunit vaccines must focus on the characterization of immunogenic epitopes, which are major targets for the immune system. The most dominant site for elicitation of neutralising immune response is located on the external envelope glycoprotein gp120 within the third variable domain (V3). To overcome virus type specificity of antibodies directed to the V3-domain we designed a 36 amino acids long gp120/V3-consensus peptide (V3-C36) based on published biological data and sequence comparisons of various HIV-1 virus isolates. This peptide contains a conserved core sequence which is suggested to form a surface-exposed beta-turn. This peptide also includes T-cell epitopes defined in mice and humans, an ADCC-epitope and two highly conserved cysteine residues which were oxidized to form a cystine derivate, thus allowing correct peptide folding. In ELISA-tests, this peptide reacts with at least 90% of randomly selected sera of European and African patients infected with HIV-1 and is recognized by three different HIV-1/V3 "type-specific" antisera (MN, RF, IIIB-strain). Using this peptide as immunogen in rabbits, antisera could be raised with highly cross-reactive and HIV-1/IIIB strain neutralizing properties. Moreover, HTLV/HIV-1/IIIB specific cytotoxic T-lymphocytes (CTLs) of BALB/c mice infected with a gp120 recombinant vaccinia virus recognized the central 16- and 12-mer peptides of the V3-C36 consensus peptide in cytolytic assays, indicating perfect compatibility of the consensus peptide with the IIIB-primed CTLs. The DNA-sequence encoding the V3-consensus loop region might be an important component in newly designed recombinant subunit vaccines. In addition, due to its broad serological reactivity, the V3-consensus peptide might play an important role in special diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456889     DOI: 10.1007/bf01309580

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  29 in total

1.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

2.  Detection of human immunodeficiency virus and other retroviruses in cell culture supernatants by a reverse transcriptase microassay.

Authors:  J P Gregersen; H Wege; L Preiss; K D Jentsch
Journal:  J Virol Methods       Date:  1988-02       Impact factor: 2.014

3.  B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.

Authors:  A R Neurath; N Strick; E S Lee
Journal:  J Gen Virol       Date:  1990-01       Impact factor: 3.891

4.  Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection.

Authors:  T Hattori; A Koito; K Takatsuki; H Kido; N Katunuma
Journal:  FEBS Lett       Date:  1989-05-08       Impact factor: 4.124

5.  Functional contribution of cysteine residues to the human immunodeficiency virus type 1 envelope.

Authors:  E Tschachler; H Buchow; R C Gallo; M S Reitz
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.

Authors:  H Takahashi; J Cohen; A Hosmalin; K B Cease; R Houghten; J L Cornette; C DeLisi; B Moss; R N Germain; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

7.  Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals.

Authors:  M Clerici; D R Lucey; R A Zajac; R N Boswell; H M Gebel; H Takahashi; J A Berzofsky; G M Shearer
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

8.  Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D C Bernstein; D L Mann; G M Shearer; J A Berzofsky
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

9.  Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.

Authors:  S Modrow; B H Hahn; G M Shaw; R C Gallo; F Wong-Staal; H Wolf
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

10.  Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein.

Authors:  H Takahashi; R Houghten; S D Putney; D H Margulies; B Moss; R N Germain; J A Berzofsky
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.